PIIND2023-07-012023-09-30 PIIND2023-07-012023-09-30 PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses02Member PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses03Member PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses04Member PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses05Member PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses06Member PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses07Member PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses08Member PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses09Member PIIND2023-07-012023-09-30in-bse-fin:OneOperatingExpenses10Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses02Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses03Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses04Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses05Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses06Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses07Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses08Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses09Member PIIND2023-07-012023-09-30in-bse-fin:FourOperatingExpenses10Member PIIND2023-09-30 PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentRevenue01Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentRevenue02Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentRevenue03Member PIIND2023-07-012023-09-30in-bse-fin:FourReportableSegmentRevenue01Member PIIND2023-07-012023-09-30in-bse-fin:FourReportableSegmentRevenue02Member PIIND2023-07-012023-09-30in-bse-fin:FourReportableSegmentRevenue03Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentResults01Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentResults02Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentResults03Member PIIND2023-07-012023-09-30in-bse-fin:FourReportableSegmentResults01Member PIIND2023-07-012023-09-30in-bse-fin:FourReportableSegmentResults02Member PIIND2023-07-012023-09-30in-bse-fin:FourReportableSegmentResults03Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentAssets01Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentAssets02Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentAssets03Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentLiabilities01Member PIIND2023-09-30in-bse-fin:OneReportableSegmentLiabilities01Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentLiabilities02Member PIIND2023-09-30in-bse-fin:OneReportableSegmentLiabilities02Member PIIND2023-07-012023-09-30in-bse-fin:OneReportableSegmentLiabilities03Member PIIND2023-09-30in-bse-fin:OneReportableSegmentLiabilities03Member PIIND2023-07-012023-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member PIIND2023-07-012023-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member PIIND2023-07-012023-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member PIIND2023-07-012023-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member PIIND2023-07-012023-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member PIIND2023-07-012023-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 523642 PIIND NOTLISTED PI Industries Limited Equity 2023-04-01 2024-03-31 2023-11-08 2023-10-26 INR Millions Half yearly 14:00:00 20:20:00 2023-11-08 2023-11-08 true Cash Flow Indirect Not applicable Multi segment 2023-07-01 2023-09-30 Unaudited Consolidated 21169000000.00 469000000.00 21638000000.00 9772000000.00 1147000000.00 392000000.00 1638000000.00 78000000.00 803000000.00 2706000000.00 16536000000.00 5102000000.00 0.00 5102000000.00 1108000000.00 -791000000.00 317000000.00 0.00 4785000000.00 0.00 0.00 0.00 20000000.00 4805000000.00 -246000000.00 4559000000.00 4805000000.00 0.00 4559000000.00 0.00 152000000.00 1 31.67 31.66 0.00 0.00 31.67 31.66 0.00 0.00 0.00 1. The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Board and approved by the Board of Directors at their meeting held on November 08, 2023. 2. Consolidated Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 3. The Consolidated financial results include the results of the following entities namely, Parent Company a) Pl Industries Limited; Subsidiaries (including step down subsidiaries): b) PILL Finance and Investments Limited c) Pl Life Science and Research Limited d) Pl Japan Co. Limited e) Jivagro Limited f) Pl Bioferma Private Limited g) Pl Fermachem Private Limited h) Pl Health Sciences Limited i) Pl Health Sciences USA, LLC j) Pl Health Sciences Netherlands BV k) Archimica S.p.A Italy; Controlled trust: I) PIl ESOP Trust; m) Pl Kumiai Private Limited (Joint Venture) n) Solinnos Agro Sciences Private Limited (Associate). 4. Statement of Consolidated Cash Flow is attached in Annexure I. 5. The Company raised Rs.20,000 million during the quarter ended 30th September 2020 through Qualified Institutional Placement (QIP) of equity shares. Out of the funds received of Rs.19,750 million (net of expense of Rs.250 million), the Company invested Rs.8,530 million (including Rs.865 million invested till March 31, 2023) in one of its subsidiary, Pl Health Sciences Limited. Balance funds of Rs.11,220 million lreceived pursuant to QIP remain invested in fixed deposits, liquid and other debt mutual funds. 6. During the June 2023 quarter, Pl Health Sciences Limited has entered into a share purchase agreement dated 27th April 2023 for the acquisition of 100% shareholding of Therachem Research Medilab (India) Private Limited and Solis Pharmachem Private Limited . Further, Pl Health Sciences USA, LLC has entered into an asset purchase agreement dated 27th April 2023 for the acquisition of business of Therachem Research Medilab LLC, USA. These agreements were subject to satisfactory completion of conditions precedents as set out in the respective agreement, which were completed on June 02, 2023 end of business hours.Pl Health Sciences Netherlands BV has entered into a share purchase agreement dated 26th April 2023 for the acquisition of 100% shareholding of Archimica S.p.A, Italy and acquired 100% shares on 27th April 2023. 7. During the current quarter, The Regional Director, Ministry of Corporate Affairs has approved the Scheme of Amalgamation of Therachem Research Medilab (India) Private Limited and Solis Pharmachem Private Limited with Pl Health Sciences Limited, on September 27, 2023 and requisite filing with the Registrar of Companies was completed on October 10, 2023. Accordingly, the Group has accounted for the merger using the pooling of interest method retrospectively from the appointed date June 02, 2023 in the consolidated results as prescribed in Ind AS- 103 - Business Combination . 8. The cost of material for the quarter includes Rs. 401 Million attributable to material lost in transit. This matter is currently under investigation. 9. Segment information as per Ind AS 108 Operating Segments is as per annexure II. Multi segment 2023-04-01 2023-09-30 Unaudited Consolidated 40273000000.00 938000000.00 41211000000.00 19491000000.00 1824000000.00 214000000.00 3373000000.00 121000000.00 1500000000.00 5179000000.00 31702000000.00 9509000000.00 0.00 9509000000.00 1915000000.00 -973000000.00 942000000.00 0.00 8567000000.00 0.00 0.00 0.00 67000000.00 8634000000.00 34000000.00 8668000000.00 8634000000.00 0.00 8668000000.00 0.00 152000000.00 1 56.91 56.90 0.00 0.00 56.91 56.90 0.00 0.00 0.00 Advertisement & Sales Promotion 204000000.00 Environment & Pollution Control Expenses 254000000.00 Freight & Cartage 156000000.00 Legal & professional fees 225000000.00 Others 725000000.00 Power, Fuel & Water 584000000.00 Provision for Bad and Doubtful debts & Advances 60000000.00 Repairs & Maintenance - Others 50000000.00 Repairs & Maintenance - Plant and machinery 248000000.00 Travelling and Conveyance 200000000.00 Advertisement & Sales Promotion 391000000.00 Environment & Pollution Control Expenses 528000000.00 Freight & Cartage 340000000.00 Legal & professional fees 493000000.00 Others 1351000000.00 Power, Fuel & Water 1104000000.00 Provision for Bad and Doubtful debts & Advances 123000000.00 Repairs & Maintenance - Others 106000000.00 Repairs & Maintenance - Plant and machinery 360000000.00 Travelling and Conveyance 383000000.00 0.00 27414000000.00 2368000000.00 0.00 3597000000.00 2197000000.00 901000000.00 0.00 297000000.00 56000000.00 0.00 0.00 870000000.00 926000000.00 63000000.00 347000000.00 38110000000.00 13998000000.00 11451000000.00 16655000000.00 6976000000.00 11129000000.00 97000000.00 42000000.00 46350000000.00 49000000.00 2767000000.00 63164000000.00 101274000000.00 152000000.00 79668000000.00 79820000000.00 79820000000.00 269000000.00 0.00 2168000000.00 2437000000.00 300000000.00 152000000.00 0.00 0.00 2889000000.00 992000000.00 12045000000.00 3598000000.00 16635000000.00 1253000000.00 322000000.00 355000000.00 0.00 18565000000.00 21454000000.00 101274000000.00 Agro Chemicals 20451000000.00 Other Income 0.00 Pharma 718000000.00 Agro Chemicals 39112000000.00 Other Income 0.00 Pharma 1161000000.00 21169000000.00 40273000000.00 21169000000.00 40273000000.00 Agro Chemicals 5055000000.00 Other Income 469000000.00 Pharma -344000000.00 Agro Chemicals 9188000000.00 Other Income 938000000.00 Pharma -496000000.00 5180000000.00 9630000000.00 78000000.00 121000000.00 -20000000.00 -67000000.00 5122000000.00 9576000000.00 Agro Chemicals 88517000000.00 Other Income 0.00 Pharma 12757000000.00 101274000000.00 0.00 101274000000.00 Agro Chemicals 17147000000.00 Other Income 0.00 Pharma 4307000000.00 21454000000.00 0.00 21454000000.00 121000000.00 1058000000.00 -5712000000.00 0.00 -1342000000.00 1000000.00 -2000000.00 -128000000.00 34000000.00 2964000000.00 0.00 26000000.00 0.00 1500000000.00 123000000.00 34000000.00 23000000.00 1126000000.00 -76000000.00 -10000000.00 0.00 684000000.00 0.00 -323000000.00 0.00 0.00 67000000.00 7000000.00 -67000000.00 -1260000000.00 8249000000.00 0.00 0.00 0.00 1552000000.00 0.00 6697000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5000000.00 2949000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 821000000.00 0.00 -5424000000.00 0.00 -7547000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 98000000.00 0.00 0.00 0.00 834000000.00 45000000.00 0.00 -120000000.00 -901000000.00 -1751000000.00 0.00 -1751000000.00 8727000000.00 6976000000.00 Remeasurements gain/(loss) on cash flow hedges 7000000.00 Remeasurements gain/(loss) on cash flow hedges 14000000.00 7000000.00 14000000.00 3000000.00 5000000.00 Effective portion of gain/(loss) on cashflow hedges -316000000.00 Exchange difference on translation of foreign operations -45000000.00 Effective portion of gain/(loss) on cashflow hedges 141000000.00 Exchange difference on translation of foreign operations -67000000.00 -361000000.00 74000000.00 -111000000.00 49000000.00